Recce Pharmaceuticals (RCE) H2 2026 earnings summary

Executive summary

• Advanced two pivotal Phase 3 clinical trials for diabetic foot infections (DFI) in Indonesia and Australia, with patient dosing underway and regulatory milestones achieved in both regions.

• Entered a non-binding licensing term sheet for RECCE® 327 covering 12 MENA countries, expanding commercial reach.

• Strengthened collaborations with the U.S. Army for burn wound infection research, supported by a $2M U.S. Department of Defense grant.

• Received significant non-dilutive funding, including an AUD $5.3M R&D tax rebate and an AUD $85M Advanced Overseas Finding for global R&D activities.

Financial highlights

• Operating loss decreased to $14.96M from $21.43M in the prior year, mainly due to reduced R&D expenditure.

• R&D tax incentive income rose to $8.88M (2025: $6.74M).

• Cash and cash equivalents at year-end were $2.69M, down from $10.45M, reflecting ongoing investment in clinical programs.

• Total equity capital raised over two years reached $22.2M, with an additional $30M debt facility available.

• Net liabilities increased to $16.72M (2025: $3.05M), with accumulated losses of $101.32M.

Outlook and guidance

• Focused on delivering interim data readouts and regulatory submissions for DFI in Indonesia and Australia.

• Targeting further licensing agreements and commercial milestones in new regions.

• Ongoing development of R327 for additional indications, including inhaled therapy for hospital-acquired pneumonia.

• Plans to leverage non-dilutive funding and equity raises to support continued R&D and market launch preparations.